Detalhe da pesquisa
1.
EMT activates exocytotic Rabs to coordinate invasion and immunosuppression in lung cancer.
Proc Natl Acad Sci U S A
; 120(28): e2220276120, 2023 07 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37406091
2.
Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function NOTCH1-Mutant Head and Neck Cancer.
Oncologist
; 27(12): 1004-e926, 2022 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36124629
3.
Membrane-Binding Cooperativity and Coinsertion by C2AB Tandem Domains of Synaptotagmins 1 and 7.
Biophys J
; 116(6): 1025-1036, 2019 03 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-30795874
4.
Joint prognostic effect of obesity and chronic systemic inflammation in patients with metastatic colorectal cancer.
Cancer
; 121(17): 2968-75, 2015 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25975416
5.
A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer.
Oncologist
; 19(10): 1040-1, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25170013
6.
Physical and chemical stability of reconstituted and diluted dexrazoxane infusion solutions.
J Oncol Pharm Pract
; 20(1): 58-64, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23676513
7.
Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights.
Nat Commun
; 15(1): 3152, 2024 Apr 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38605064
8.
Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.
Lancet Oncol
; 13(8): 827-37, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22759480
9.
IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC.
Clin Cancer Res
; 29(7): 1292-1304, 2023 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36595561
10.
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation.
Cancer Chemother Pharmacol
; 92(2): 107-118, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37314501
11.
Distinct patterns of auto-reactive antibodies associated with organ-specific immune-related adverse events.
Front Immunol
; 14: 1322818, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38152395
12.
A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer.
Cancer
; 118(9): 2378-84, 2012 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22006179
13.
Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection.
Lung Cancer
; 164: 69-75, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35038676
14.
Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC).
Invest New Drugs
; 29(3): 499-505, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-20094773
15.
Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470.
Nat Med
; 10(3): 255-61, 2004 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-14981512
16.
Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC.
J Thorac Oncol
; 16(4): 601-609, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33388476
17.
Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling.
JCO Precis Oncol
; 52021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34377884
18.
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.
Nat Med
; 27(3): 504-514, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33603241
19.
Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells.
Mol Cancer Ther
; 8(3): 521-32, 2009 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-19276160
20.
Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment.
Clin Cancer Res
; 26(20): 5477-5486, 2020 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32816946